Zack Garrett’s practice focuses on patent litigation under the Hatch-Waxman Act in the chemical and pharmaceutical areas.
During law school, Mr. Garrett was a member of the editorial staff for the Columbia Science and Technology Law Review.
Gilead Pharmasset LLC v. Idenix Pharmaceuticals, Inc., et al.
Member of the team that represented Gilead in a second patent interference against Idenix. This interference related to methods for treating HCV infection using nucleoside analogs. In an earlier motions decision, Fitzpatrick was successful in having all of Idenix’s involved patent claims held unpatentable and in obtaining senior party status for Gilead.